Aktuellt
SENASTE
Redeye leaves a short comment on the Q3 report of Asarina Pharma. As expected, following the discontinuation of sepranolone in menstrual migraine, the cash burn has been significantly reduced as we await the initiation of phase II sepranolone study in Tourette.
LÄS MER
